161 related articles for article (PubMed ID: 26816001)
1. Lack of anti-tumor activity by anti-VEGF treatments in hepatic hemangiomas.
Lee M; Choi JY; Lim JS; Park MS; Kim MJ; Kim H
Angiogenesis; 2016 Apr; 19(2):147-53. PubMed ID: 26816001
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
3. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
[TBL] [Abstract][Full Text] [Related]
4. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
[TBL] [Abstract][Full Text] [Related]
5. A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report.
Ono M; Sawada K; Okumura T
Clin J Gastroenterol; 2017 Feb; 10(1):63-67. PubMed ID: 27995469
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
7. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.
Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K
Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077
[TBL] [Abstract][Full Text] [Related]
8. Assessing normal growth of hepatic hemangiomas during long-term follow-up.
Hasan HY; Hinshaw JL; Borman EJ; Gegios A; Leverson G; Winslow ER
JAMA Surg; 2014 Dec; 149(12):1266-71. PubMed ID: 25321079
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
10. Early development of sunitinib in hepatocellular carcinoma.
Zhu AX; Raymond E
Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of hepatic hemangiomas by ultrasonography: with emphasis on the growth rate of the tumor.
Yeh WC; Yang PM; Huang GT; Sheu JC; Chen DS
Hepatogastroenterology; 2007 Mar; 54(74):475-9. PubMed ID: 17523302
[TBL] [Abstract][Full Text] [Related]
13. Management of liver hemangiomas according to size and symptoms.
Erdogan D; Busch OR; van Delden OM; Bennink RJ; ten Kate FJ; Gouma DJ; van Gulik TM
J Gastroenterol Hepatol; 2007 Nov; 22(11):1953-8. PubMed ID: 17914976
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
15. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
17. Embolization for management of hepatic hemangiomas.
Deutsch GS; Yeh KA; Bates WB; Tannehill WB
Am Surg; 2001 Feb; 67(2):159-64. PubMed ID: 11243541
[TBL] [Abstract][Full Text] [Related]
18. Radiofrequency ablation for large hepatic hemangiomas: initial experience and lessons.
Gao J; Ke S; Ding XM; Zhou YM; Qian XJ; Sun WB
Surgery; 2013 Jan; 153(1):78-85. PubMed ID: 22853860
[TBL] [Abstract][Full Text] [Related]
19. Single-pass CT of hepatic tumors: value of globular enhancement in distinguishing hemangiomas from hypervascular metastases.
Leslie DF; Johnson CD; MacCarty RL; Ward EM; Ilstrup DM; Harmsen WS
AJR Am J Roentgenol; 1995 Dec; 165(6):1403-6. PubMed ID: 7484574
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation.
Park SY; Tak WY; Jung MK; Jeon SW; Cho CM; Kweon YO; Kim KC
J Hepatol; 2011 Mar; 54(3):559-65. PubMed ID: 21115209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
